David Meeker, speaking at World Orphan Drug Congress 2011

David Meeker,
COO
Genzyme

David P. Meeker is responsible for Genzyme’s commercial organization, overseeing the business units, country management organization and global market access functions. He works to maximize the potential of the company’s broad portfolio of products, most of which are in their growth phases.

Dr. Meeker joined Genzyme in 1994 as Medical Director to work on the Cystic Fibrosis Gene Therapy program. Subsequently, as Vice President, Medical Affairs, he was responsible for the development of therapeutic products, including treatments in the current LSD portfolio.

He was promoted to Senior Vice President in 1998, and in 2000 became the Business Unit Leader for Genzyme’s Lysosomal Storage Disease and Thyrogen programs in Europe. Dr. Meeker was promoted to President of the Global LSD business unit in 2003. In this role, he oversaw the global launches of Aldurazyme, Fabrazyme and Myozyme. In 2008, he was promoted to Executive Vice President of Therapeutics, Biosurgery and Transplant. He has held his current position since 2009.

Prior to joining Genzyme, Dr. Meeker was the Director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic and an assistant professor of medicine at Ohio State University. He has authored more than 40 articles and multiple book chapters.

Dr. Meeker is a board member of Penwest Pharmaceuticals Inc. He is also a board member of Prize4Life, an organization dedicated to accelerating the discovery of treatments for amyotrophic lateral sclerosis.

Dr. Meeker attended Dartmouth College and received his M.D. from the University of Vermont Medical School. He completed an Internal Medicine residency at Beth Israel Hospital in Boston and a Pulmonary/Critical Care fellowship at Boston University. He completed the Advanced Management Program at Harvard Business School in 2000

Appearing:

World Orphan Drug Congress Day 2 Wednesday 30th November 2011

9.10am

From large to small: the critical elements of orphan drug success

How are the research objectives of all sized organisations becoming merged?
What do different organisational cultures and sizes think about being successful?
How should alliances be formed both to achieve success and following proof of orphan drug development?
What are the take home messages for achieving market access, creating successful clinical trials and interacting with the disease patient group?

David Meeker,

COO,
Genzyme

Sponsor World Orphan Drug Congress 2011 ›

Associate Sponsor